17 min
Beyond BCMA: Exploring Talquetamab in Myeloma Therapy ASTCT Talks
-
- Medicine
In this latest episode of ASTCT Talks, Dr. Rahul Banerjee, MD, FACP, sits down with Dr. Amrita Krishnan, MD. They delve into the use of GPRC5D as a target in myeloma therapy, specifically focusing on Talquetamab.
Dr. Krishnan shares insights from the MonumenTAL-1 trial, discussing the dosing schedules and response rates with GPRC5D-targeted therapy. They explore the unique toxicities associated with this treatment, such as cytokine release syndrome and skin and nail toxicities. The conversation also touches on the considerations for patients who have previously received BCMA-targeted therapies and the potential of GPRC5D-targeted therapy in improving outcomes.
Tune in to learn about the evolving landscape of myeloma treatment beyond BCMA.
About Dr. Rahul Banerjee, MD, FACP
Dr. Rahul Banerjee, MD, FACP, (@RahulBanerjeeMD) is an Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington. His clinical interests are in multiple myeloma and CAR-T therapy. He has authored over 60 peer-reviewed publications with a research emphasis on reducing toxicities and improving the patient experience during treatment for multiple myeloma.
About Dr. Amrita Krishnan, MD
Dr. Amrita Krishnan, MD (@DoctorAKrishnan) directs the Judy and Bernard Briskin Center for Multiple Myeloma Research at City of Hope, seeking to make gains in one of the most rapidly changing areas in cancer research.
A key member of the City of Hope team since 1996, Dr. Krishnan trained at The University of Rochester, Beth Israel Hospital, Fred Hutchinson Research Cancer Center and Dana Farber Cancer Institute. She serves as a steering committee member on the Multiple Myeloma Research Foundation and the North American representative to the International Myeloma Society, former chair of the Blood and Marrow Transplant Clinical Trials Network myeloma committee and is the Co-Chair of several of the largest myeloma transplant trials in the U.S.
Her research interests are in development of new drugs for relapsed myeloma and understanding mechanisms of disease resistance.
In this latest episode of ASTCT Talks, Dr. Rahul Banerjee, MD, FACP, sits down with Dr. Amrita Krishnan, MD. They delve into the use of GPRC5D as a target in myeloma therapy, specifically focusing on Talquetamab.
Dr. Krishnan shares insights from the MonumenTAL-1 trial, discussing the dosing schedules and response rates with GPRC5D-targeted therapy. They explore the unique toxicities associated with this treatment, such as cytokine release syndrome and skin and nail toxicities. The conversation also touches on the considerations for patients who have previously received BCMA-targeted therapies and the potential of GPRC5D-targeted therapy in improving outcomes.
Tune in to learn about the evolving landscape of myeloma treatment beyond BCMA.
About Dr. Rahul Banerjee, MD, FACP
Dr. Rahul Banerjee, MD, FACP, (@RahulBanerjeeMD) is an Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington. His clinical interests are in multiple myeloma and CAR-T therapy. He has authored over 60 peer-reviewed publications with a research emphasis on reducing toxicities and improving the patient experience during treatment for multiple myeloma.
About Dr. Amrita Krishnan, MD
Dr. Amrita Krishnan, MD (@DoctorAKrishnan) directs the Judy and Bernard Briskin Center for Multiple Myeloma Research at City of Hope, seeking to make gains in one of the most rapidly changing areas in cancer research.
A key member of the City of Hope team since 1996, Dr. Krishnan trained at The University of Rochester, Beth Israel Hospital, Fred Hutchinson Research Cancer Center and Dana Farber Cancer Institute. She serves as a steering committee member on the Multiple Myeloma Research Foundation and the North American representative to the International Myeloma Society, former chair of the Blood and Marrow Transplant Clinical Trials Network myeloma committee and is the Co-Chair of several of the largest myeloma transplant trials in the U.S.
Her research interests are in development of new drugs for relapsed myeloma and understanding mechanisms of disease resistance.
17 min